All Relations between asymmetrical (pato 0000616) and nitrogen monoxide

Reference Sentence Publish Date Extraction Date Species
Valmore Berm\\xc3\\xbadez, Fernando Berm\\xc3\\xbadez, Guillermo Acosta, Alejandro Acosta, Johnny A\\xc3\\xb1ez, Carla Andara, Elliuz Leal, Cl\\xc3\\xadmaco Cano, Velasco Manuel, Rafael Hern\\xc3\\xa1ndez, Zafar Israil. Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition. American journal of therapeutics vol 15 issue 4 2008 18645335 a decline in nitric oxide bioavailability may be caused by decreased expression of the endothelial nitric oxide synthase, a reduction of substrate or cofactors for this enzyme, alterations of cellular signaling, enzyme inhibition by asymmetric dimethyl arginine, and, finally, accelerated nitric oxide degradation by reactive oxygen species. 2008-09-16 2022-01-13 Not clear
Aytekin Oguz, Mehmet Uzunlul. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. International heart journal vol 49 issue 3 2008 18612188 elevated concentrations of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase, are associated with endothelial dysfunction. 2008-08-26 2022-01-13 Not clear
Zhi Zhou, De-Jian Jiang, Su-Jie Jia, Hong-Bo Xiao, Bo Xiao, Yuan-Jian L. Down-regulation of endogenous nitric oxide synthase inhibitors on endothelial SK3 expression. Vascular pharmacology vol 47 issue 5-6 2008 17869187 to investigate role of endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) in down-regulation of the expression of endothelial sk3 in atherosclerosis. 2008-08-21 2022-01-12 Not clear
Ay\\xc5\\x9fe Ye\\xc5\\x9fim G\\xc3\\xb6\\xc3\\xa7men, Emel Sahin, H\\xc3\\xbcseyin Ko\\xc3\\xa7ak, Murat Tuncer, Saadet G\\xc3\\xbcm\\xc3\\xbc\\xc5\\x9fl\\xc3\\xb. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. Clinical biochemistry vol 41 issue 10-11 2008 18457672 levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. 2008-08-06 2022-01-12 Not clear
Ay\\xc5\\x9fe Ye\\xc5\\x9fim G\\xc3\\xb6\\xc3\\xa7men, Emel Sahin, H\\xc3\\xbcseyin Ko\\xc3\\xa7ak, Murat Tuncer, Saadet G\\xc3\\xbcm\\xc3\\xbc\\xc5\\x9fl\\xc3\\xb. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. Clinical biochemistry vol 41 issue 10-11 2008 18457672 in this study, we aimed to investigate the activities of paraoxonase-1 (pon1) and nitric oxide synthase (nos) and the levels of asymmetric dimethylarginine (adma), nitric oxide (no), oxidized low-density lipoprotein (oxldl), ceruloplasmin (cp), thiobarbituric acid-reactive substances (tbars), malondialdehyde (mda), 4-hydroxynonenal (hne) and lipids in serum of patients with end-stage renal disease (esrd) having continuous ambulatory peritoneal dialysis (capd) treatment and controls living in the antalya region, turkey. 2008-08-06 2022-01-12 Not clear
Guo-Gang Zhang, Yong-Ping Bai, Mei-Fang Chen, Rui-Zhen Shi, De-Jian Jiang, Qiong-Mei Fu, Gui-Shan Tan, Yuan-Jian L. Asymmetric dimethylarginine induces TNF-alpha production via ROS/NF-kappaB dependent pathway in human monocytic cells and the inhibitory effect of reinioside C. Vascular pharmacology vol 48 issue 2-3 2008 18295546 asymmetric dimethylarginine induces tnf-alpha production via ros/nf-kappab dependent pathway in human monocytic cells and the inhibitory effect of reinioside c. asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase (nos) inhibitor, has been implicated in vascular inflammation through induction of reactive oxygen species (ros) and proinflammatory genes in endothelial cells. 2008-07-28 2022-01-12 Not clear
Precious P Landburg, Tom Teerlink, Frits A J Muskiet, Ashley J Duits, John-John B Schno. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. American journal of hematology vol 83 issue 7 2008 18383318 plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. 2008-07-18 2022-01-12 Not clear
Precious P Landburg, Tom Teerlink, Frits A J Muskiet, Ashley J Duits, John-John B Schno. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. American journal of hematology vol 83 issue 7 2008 18383318 plasma concentrations of asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase inhibitor, are elevated in the clinically asymptomatic state of sickle cell disease (scd). 2008-07-18 2022-01-12 Not clear
Ugur Bozlar, Mehmet Sahin Ugurel, Omer Ozcan, Erdinc Cakir, Bahri Ustunsoz, Taner Ucoz, Cumhur Bilgi, Ibrahim Somunc. Impact of catheter arteriography on the serum level of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase. Cardiovascular and interventional radiology vol 31 issue 3 2008 18299922 impact of catheter arteriography on the serum level of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase. 2008-07-16 2022-01-12 Not clear
Lawrence J Druhan, Scott P Forbes, Arthur J Pope, Chun-An Chen, Jay L Zweier, Arturo J Cardoune. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry vol 47 issue 27 2008 18553936 the endogenous methylarginines, asymmetric dimethylarginine (adma) and n (g)-monomethyl- l-arginine (l-nmma) regulate nitric oxide (no) production from endothelial no synthase (enos). 2008-07-16 2022-01-12 Not clear
Mei Feng, Lihua Liu, Zheng Guo, Yan Xion. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine. European journal of pharmacology vol 584 issue 1 2008 18342305 dimethylarginine dimethylaminohydrolase (ddah) is a key enzyme responsible for the metabolism of nitric oxide (no) synthase (nos) inhibitor asymmetric dimethylarginine (adma), and ddah2 is the predominant isoform in vascular endothelium. 2008-07-10 2022-01-12 Not clear
Halfize Uzun, Dildar Konukoglu, Mine Besler, Fusun Erdenen, Can Sezgin, Cuneyt Muderrisogl. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clinical and investigative medicine. Medecine clinique et experimentale vol 31 issue 1 2008 18312743 the effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and c-reactive protein levels. 2008-06-17 2022-01-12 Not clear
Halfize Uzun, Dildar Konukoglu, Mine Besler, Fusun Erdenen, Can Sezgin, Cuneyt Muderrisogl. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clinical and investigative medicine. Medecine clinique et experimentale vol 31 issue 1 2008 18312743 asymmetric dimethylarginine (adma), nitric oxide (nox), and c-reactive protein (crp) are important risk factors for endothelial dysfunction and mortality in the end stage renal diseases population. 2008-06-17 2022-01-12 Not clear
Anjali Desai, Ying Zhao, Jeffrey S Warre. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association vol 23 issue 5 2008 18204093 human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. 2008-06-12 2022-01-12 Not clear
Anjali Desai, Ying Zhao, Jeffrey S Warre. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association vol 23 issue 5 2008 18204093 pathophysiologic concentrations of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase (nos), are found in patients with crd and correlate with vascular disease and cardiovascular mortality. 2008-06-12 2022-01-12 Not clear
Li Wang, Yuan Zhou, Jun Peng, Zhe Zhang, De-Jian Jiang, Yuan-Jian L. Role of endogenous nitric oxide synthase inhibitor in gastric mucosal injury. Canadian journal of physiology and pharmacology vol 86 issue 3 2008 18418436 to explore the role of the endogenous nitric oxide synthase (nos) inhibitor asymmetric dimethylarginine (adma) in gastric mucosal injury, 3 models of gastric mucosal injury induced by ethanol, indomethacin, or cold stress were used in rats. 2008-06-12 2022-01-12 Not clear
Luciano Potena, William F Fearon, Karsten Sydow, Cecile Holweg, Helen Luikart, Clifford Chin, Dana Weisshaar, Edward S Mocarski, David B Lewis, Hannah A Valantine, John P Cook. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus. Transplantation vol 85 issue 6 2008 18360263 a potential contributor to endothelial pathobiology is asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase inhibitor. 2008-06-06 2022-01-12 Not clear
R M Plut. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Acta neurochirurgica. Supplement vol 104 issue 2008 18456999 however, a transient enos dysfunction evoked by an increase of the endogenous competitive nitric oxide synthase (nos) inhibitor, asymmetric dimethyl-arginine (adma), prevents this vasodilation. 2008-06-04 2022-01-12 Not clear
Angelo Zinellu, Antonio Pinna, Salvatore Sotgia, Elisabetta Zinellu, Maria Franca Usai, Francesco Carta, Leonardo Gaspa, Luca Deiana, Ciriaco Carr. Increased plasma asymmetric dimethylarginine (ADMA) levels in retinal venous occlusive disease. Clinical chemistry and laboratory medicine vol 46 issue 3 2008 18254706 we investigated the levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma), as well as homocysteine and cysteine thiols, in a cohort of subjects affected by retinal vein occlusion (rvo) disease. 2008-05-28 2022-01-12 Not clear
Catherine Martin, James Cameron, Barry McGrat. Mechanical and circulating biomarkers in isolated clinic hypertension. Clinical and experimental pharmacology & physiology vol 35 issue 4 2008 18307729 nitrite/nitrate, von willebrand factor, endothelin-1) and/or circulating levels of inhibitors of vascular nitric oxide (plasma asymmetric dimethylarginine, homocysteine), has been shown to be present in established hypertension and to a variable and inconsistent extent in subjects with icht. 2008-05-22 2022-01-12 Not clear
Page: 
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54